Brief: Geneuro Researchers Detect HERV-W ENV IN Covid-19 Patients

Geneuro SA

15/04/2021 06:43

April 15 (Reuters) - GENEURO SA  GNRO.PA :
    * GENEURO: RESEARCHERS DETECT HERV-W ENV IN COVID-19
PATIENTS AND
LINK EXPRESSION TO DISEASE SEVERITY
    * HERV-W ENV'S PRO-INFLAMMATORY PROPERTIES THOUGHT TO ACT AS
AN
"ACCELERANT" OF ACTIVATION OF INNATE IMMUNE SYSTEM, FUELING
SEVERITY OF COVID-19 EVOLUTION AND IMPACTING LONG TERM RECOVERY
    * PRELIMINARY DATA AVAILABLE ON RESEARCH SQUARE ALSO SHOWS
HERV-W
ENV EXPRESSION IN LYMPHOCYTES FOLLOWING IN VITRO EXPOSURE TO
SARS-COV-2 IN ABOUT 20% OF HEALTHY BLOOD DONORS, SUGGESTING
INDIVIDUAL SUSCEPTIBILITY
    * WITH HERVS AS A POSSIBLE AGGRAVATING AGENT OF COVID-19,
GENEURO'S TEMELIMAB, AN ANTI-HERV-W ENV MONOCLONAL ANTIBODY
ALREADY IN PHASE II CLINICAL TRIALS WITH AN EXCELLENT
TOLERABILITY AND SAFETY, COULD, WITHOUT ANY PREJUDICE TO ITS
EXISTING PROGRAMS, START TESTS AGAINST COVID-19 AS EARLY AS THIS
SUMMER

Source text for Eikon:  ID:nBwbfTF6ra 
Further company coverage:  GNRO.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))